|
Aug 1
|
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
|
|
Jul 30
|
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
|
|
Jun 27
|
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
|
|
May 30
|
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
|
May 15
|
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
|
|
May 10
|
ADC Therapeutics First Quarter 2024 Earnings: In Line With Expectations
|
|
May 9
|
Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)
|
|
May 9
|
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
|
|
May 9
|
ADC Therapeutics SA (NYSE:ADCT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
|
|
May 7
|
ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
|
|
May 6
|
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
|
|
May 6
|
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 6
|
ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial
|
|
May 6
|
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
|
|
May 6
|
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
|
|
May 1
|
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
|
|
Apr 4
|
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
|
|
Apr 3
|
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
|
|
Apr 1
|
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
|
|
Mar 16
|
US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results
|